Campbell & CO Investment Adviser LLC Increases Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Campbell & CO Investment Adviser LLC boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1,802.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 412,518 shares of the biotechnology company’s stock after purchasing an additional 390,834 shares during the period. Campbell & CO Investment Adviser LLC owned about 0.20% of BioCryst Pharmaceuticals worth $3,696,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of BCRX. Allianz Asset Management GmbH lifted its stake in shares of BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 1,200 shares during the last quarter. Royal Bank of Canada raised its holdings in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of BioCryst Pharmaceuticals by 2.6% during the first quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock valued at $685,000 after buying an additional 2,291 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at about $32,000. Finally, R Squared Ltd boosted its holdings in shares of BioCryst Pharmaceuticals by 84.2% in the 1st quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 5,335 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BCRX shares. Zacks Research cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Barclays reduced their price target on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 8th. Evercore ISI restated an “in-line” rating and set a $8.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Finally, TD Cowen began coverage on BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target for the company. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $19.33.

Insider Activity

In related news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company’s stock, valued at $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.10% of the stock is currently owned by insiders.

BioCryst Pharmaceuticals Trading Up 0.9%

NASDAQ:BCRX opened at $7.09 on Friday. The company has a market capitalization of $1.49 billion, a P/E ratio of -39.39 and a beta of 1.09. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The firm has a fifty day simple moving average of $7.45 and a 200-day simple moving average of $8.67.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The company had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same period last year, the business earned ($0.07) EPS. BioCryst Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.